the ADBL report

Issue #88, November 2015

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

In this issue:

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on September 22, 2015. The Committee reviewed Manufacturer submissions for forty-eight (48) Drug Products for potential listing, or change in listing, on the *ADBL*. The Committee also considered information for a number of supplementary assessments of the coverage status of twelve (12) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, thirty-two (32) Drug Products underwent Expedited Review for listing on the *ADBL* effective October 1, 2015, and five (5) Drug Products underwent Expedited Review for listing on the *ADBL* effective November 1, 2015.

The following are highlights of recent changes to the *ADBL* and other topics of general interest. A complete list of changes, as well as the full *ADBL* may be accessed at https://www.ab.bluecross.ca/dbl/publications.html

Highlights of Products Originally Reviewed via the Common Drug Review (CDR)

The following Drug Products were reviewed by CDR and the Expert Committee and added to the *ADBL* via Step Therapy/Special Authorization effective October 1, 2015:

- **INVOKANA*** (canagliflozin) (JAI) **100 mg & 300 mg tablets**

The following Drug Products were reviewed by CDR and the Expert Committee and added to the *ADBL* via Special Authorization (SA) effective October 1, 2015:

- **DIACOMIT*** (stiripentol) (BCF) **250 mg & 500 mg capsules and 250 mg & 500 mg oral powder packets**

The following Drug Products were reviewed by CDR and the Expert Committee and added to the *ADBL* via SA effective November 1, 2015:

- **APTIOM*** (eslicarbazepine acetate) (SUN) **200 mg, 400 mg, 600 mg & 800 mg tablets**
- **MODERIBA*** (ribavirin) (ABV) **200 mg, 400 mg & 600 mg tablets**

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.html.
Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (11/2015)

Highlights of Non-Interchangeable Old Drug Products Added

The following Non-Interchangeable Old Drug Product has been added to the *ADBL* effective November 1, 2015:

- **JAMP-NYSTATIN** (nystatin) (JPC) **100,000 unit/mL oral suspension**

Highlights of Line Extension Drug Products Reviewed for the ADBL

The following Drug Product was added to the *ADBL* as a Restricted Benefit effective November 1, 2015:

- **ASMANEX TWISTHALER** (mometasone furoate) (MFC) **100 mcg/dose metered inhalation powder**

The following Drug Products were added as Regular Benefits effective November 1, 2015:

- **FRAGMIN** (dalteparin sodium) (PFI) **3,500 IU/0.28 mL injection**
- **APO-VALACYCLOVIR** (valacyclovir) (APX) **1000 mg caplet**

The following Drug Products were reviewed but **NOT** added as they did not offer a therapeutic advantage:

- **TOUJEO SOLOSTAR** (insulin glargine) (SAV) **300 unit/mL injection**
- **VYVANSE** (lisdexamfetamine dimesylate) (SHB) **10 mg capsule**

Highlights of Other Products Reviewed but Not Added

- **TARGIN** (oxycodone HCL/ naloxone HCL) (PUR) **5 mg/2.5 mg, 10 mg/5 mg, 20 mg/10 mg & 40 mg/20 mg extended-release tablets** were reviewed but not added as they fail to offer a therapeutic advantage.

In keeping with recommendations from the CDR, the following Drug Products have NOT been added to the *ADBL*:

- **OTEZLA & OTEZLA STARTER PACK** (apremilast) (CLG) **30 mg & 10 mg/20 mg/30 mg tablets**
- **DYMISTA** (fluticasone propionate/ azelastine hydrochloride) (MDP) **50 mcg/137 mcg metered dose nasal spray**

Highlights of Interchangeable Drug Products Reviewed

The following Drug Products were reviewed by the Expert Committee and added to the *ADBL* effective November 1, 2015*:*

- **APO-DEXTROAMPHETAMINE** (dextroamphetamine sulfate) (APX) **5 mg tablet**
- **APO-VALACYCLOVIR** (valacyclovir) (APX) **500 mg caplet**
- **METHOTREXATE (PRESERVED)** (methotrexate sodium) (SDZ) **25 mg/mL injection USP**
- **MOVISSE** (norethindrone) (FMP) **0.35 mg tablet**
- **MYLAN-GLICLAZIDE MR** (gliclazide) (MYP) **30 mg sustained-release tablet**
- **MYLAN-VALACYCLOVIR** (valacyclovir) (MYP) **500 mg caplet**
- **PMS-VALACYCLOVIR** (valacyclovir) (PMS) **500 mg caplet**
- **VAN-GABAPENTIN** (gabapentin) (VAN) **100 mg, 300 mg & 400 mg capsules**

The following Drug Products were reviewed by the Expert Committee and added via Restricted Benefit/ Special Authorization effective November 1, 2015*:*

- **MINT-RIZATRIPTAN ODT** (rizatriptan benzoate) (MPI) **5 mg & 10 mg orally disintegrating tablets**

Highlights of Product Listing Changes

The following Drug Products were reviewed by the Expert Committee, and in order to enable improved patient access, these products were changed from Special Authorization to Regular Benefits on the *ADBL* effective November 1, 2015*:*

- **Valganciclovir HCL** (VALCYTE, Teva and Apotex brands) **450 mg tablets,** and **Valganciclovir HCL** (VALCYTE brand) **50 mg/mL oral suspension**

Special Authorization Criteria Changes

The Special Authorization criteria for coverage for the following Drug Products have been revised effective October 1, 2015:

- **TYSABRI*** (natalizumab) (BIO) **20 mg/mL (15 mL) injection**
- **ELIQUIS*** (apixaban) (BMS) **2.5 mg & 5 mg tablets**

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.html.

Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (11/2015)